RxSight price to sales ratio RXST

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: 1.6×
5-year median: 10.5×
Against its 5-year history: 3rd; percentile: 0 is its lowest day, 100 its highest
5-year range: 1.5× to 25.7×
Peer median: 1.6×

RxSight's price to sales ratio is 1.6× as of Oct 23, 2026.

That is below its 5-year median of 10.5×, lower than on 97% of days in the last 5 years.

Over that time it ranged from 1.5× in Oct 2026 to 25.7× in Feb 2024.

The median for 10 medical instruments and supplies stocks of a similar size is 1.6×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.6×	1.5×	3.0×
2025	3.2×	2.0×	11.3×
2024	10.8×	10.6×	25.7×
2023	18.9×	8.6×	19.7×
2022	8.5×	7.6×	16.5×

Against its peers

Companies in Medical - Instruments & Supplies nearest RxSight's size, closest first, today.

Company	Price to sales ratio
RXSTRxSight	1.6×
PDEXPro DEX	2.6×
UTMDUtah Medical Products	6.5×
INFUInfuSystem	1.9×
EMBCEmbecta	0.4×
KEQUKewaunee Scientific	0.3×
TCMDTactile Systems Technology	1.5×
MDXGMimedx	1.6×
MOVMovado	1.0×
APTAlpha Pro Tech	0.9×
IRMDIradimed	12.7×
Peer median	1.6×

Where RxSight ranks

#43of 116Medical instruments and supplies stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on RxSight

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.